Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors

NCT07769047 · Not yet recruiting

Last updated 2026-08-27

This trial is testing whether the medication semaglutide, combined with lifestyle support, can improve heart and blood vessel health in postmenopausal women who are obese and have survived early-stage breast cancer while taking aromatase inhibitors.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind supportive care study

Participants 50 people Planned (estimated).

Who can join Ages 46–55 · female only

Timeline Started 2026-09 · est. completion 2035-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07769047 ↗

Description as written by the study sponsor.

This phase IV trial studies whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors (BCS) who are taking an aromatase inhibitor. In postmenopausal BCS who are taking an aromatase inhibitor, obesity raises the risk of heart and blood vessel problems. Semaglutide is a medicine approved by the United States Food and Drug Administration for weight loss and for lowering the risk of heart events in people with heart disease. The structured lifestyle support in this trial includes counseling on nutrition and physical activity which provides specific recommendations for individuals to follow.

Treatments tested

Biospecimen Collection also known as Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection Procedure

Undergo blood sample collection
Dual X-ray Absorptiometry also known as BMD scan, bone mineral density scan, DEXA, DEXA (Bone Density), DEXA Scan, dual energy x-ray absorptiometric scan, Dual Energy X-ray Absorptiometry, Dual X-Ray Absorptometry, DXA, DXA SCAN Procedure

Undergo DEXA
Functional Assessment Other

Undergo vascular function testing
Lifestyle Counseling Behavioral

Receive structured lifestyle intervention recommendations
Semaglutide also known as Ozempic, Rybelsus, Wegovy Drug

Given SC

Main thing measured	Change in PWV between arms (Aim 1)
Sponsor	Mayo Clinic
Conditions studied	Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07769047 ↗